Drug Profile
Mecamylamine ophthalmic - CoMentis
Alternative Names: ATG 003; ATG-3Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator CoMentis
- Class Eye disorder therapies; Norbornanes; Small molecules
- Mechanism of Action Nicotinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Age-related macular degeneration; Diabetic macular oedema